SCHEMBL13801372

SCHEMBL13801372

O=CN1CCC(n2cc(-c3cccc(O)c3)[nH]c2=O)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.52
DRD4 P21917 1/20 0.52
DRD3 P35462 1/20 0.52
CALCRL Q16602 7/20 0.43
TNKS O95271 1/20 0.41
CCR5 P51681 1/20 0.40
KCNH2 Q12809 1/20 0.40
RAMP1 O60894 2/20 0.39
ADORA3 P0DMS8 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
PIK3CD O00329 3/20 0.37
PIK3CA P42336 3/20 0.37
PIK3CB P42338 3/20 0.37
PIK3CG P48736 3/20 0.37
ABL1 P00519 1/20 0.35
EGFR P00533 1/20 0.35
LCK P06239 1/20 0.35
SRC P12931 1/20 0.35
ABL2 P42684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13801273 0.86 DRD2 (0.67) DRD2DRD4DRD3CALCRLTNKS
SCHEMBL13801347 0.86 DRD2 (0.52) DRD2DRD4DRD3CALCRLTNKS
SCHEMBL13801364 0.86 DRD2 (0.55) DRD2DRD4DRD3CALCRLTNKS
SCHEMBL13801360 0.84 DRD2 (0.64) DRD2DRD4DRD3CALCRLTNKS
SCHEMBL13801338 0.83 DRD2 (0.49) DRD2DRD4DRD3CALCRLTNKS
SCHEMBL3959127 0.83 FGR (0.48) DRD2DRD4DRD3CALCRLTNKS
SCHEMBL14098803 0.83 DRD2 (0.57) DRD2DRD4DRD3CALCRLTNKS
SCHEMBL13801361 0.82 DRD2 (0.50) DRD2DRD4DRD3CALCRLTNKS
SCHEMBL13801346 0.82 DRD2 (0.48) DRD2DRD4DRD3CALCRLTNKS
SCHEMBL13801351 0.78 DRD2 (0.53) DRD2DRD4DRD3CALCRLTNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163480-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production DR. KARL THOMAE GMBH (DE) 2009-06-25 US disclosed
US-20090163480-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production DR. KARL THOMAE GMBH (DE) 2009-06-25 US disclosed
US-7498325-B2 Modified amino acids, pharmaceuticals containing these compounds and method for their production KARL THOMAS GMBH (DE) 2009-03-03 US disclosed
US-7498325-B2 Modified amino acids, pharmaceuticals containing these compounds and method for their production KARL THOMAS GMBH (DE) 2009-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163480-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production PTMS, CHRM1, SRMS DRD2 187/4885DRD4 139/4885DRD3 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.